[ad_1]
BEIJING (Reuters) – The US pharmaceutical group Beogen and its Japanese partner Isai have decided to finalize two adocanumab trials for the treatment of Alzheimer's disease, which is a major setback for efforts to find curative treatment, according to eyewitnesses.
The experts considered the drug as one of the latest experiments on the assumption that removing amyloid sediment from the patient's brain during the early stages of the disease could put an end to the deterioration of the disease; which includes memory loss and personal care.
Peugeot shares plunged nearly 30% after the decision, reaching 225.70 dollars, the largest decline since February 2005.
The decision to discontinue the tests came after an independent monitoring body stated that there was more hope in the success of the tests based on the ## 147 ## # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # 39, analysis of property data.
In July, Essay announced promising results for another Alzheimer's disease drug, PEN-2401, which is developed in collaboration with Peugeot and which failed after 12 months of analysis.
Any effective treatment for Alzheimer's disease, which affects approximately 5.7 million Americans, will certainly be one of the best-selling drugs in the world, but efforts made to date have not helped. have not borne fruit, more than 100 experimental drugs have failed.
Clinical trials were in the final stages of the adocanumab test in patients with mild cognitive impairment or mild dementia, and the detailed findings will be presented at an upcoming medical meeting.
"This disappointing news underscores the very difficult treatment of Alzheimer's disease and the need to further enhance neuroscience," said Michael Fontaineos, CEO of Peugeot.
Biogen and Isai said they would continue to work on other treatments for the disease, including BNN 2401.
[ad_2]
Source link
